Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis

NCT04102241 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

216

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: 15mg Hemay005
DRUG: Placebos

Sponsor

Tianjin Hemay Pharmaceutical Co., Ltd